Investigational drug · Phase 2
9MW1911
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Chronic Obstructive Pulmonary Disease COPD.
Phase 2Last checked: Nov 20, 2026Latest source record: Dec 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "9MW1911"
First trial start
2023
Jul 6, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "9MW1911", any sponsor or status.
Conditions studied
As listed on its trial records.
- Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Chronic Obstructive Pulmonary Disease COPD
Approved drugs for the same conditions: COPD · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "9MW1911" as an intervention, largest first.
- A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingRecruiting
Mabwell (Shanghai) Bioscience Co., Ltd.Industry
NCT07292714 · 360 participants (planned) · Start Jul 15, 2025 · Primary completion Dec 2027
Drug: 9MW1911; Phase II placebo · For: Chronic Obstructive Pulmonary Disease COPD
Sites: Chizhou, China; Hefei, China; Lanzhou, China · 51 sites in all
- Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).Active, not recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.Industry
NCT06175351 · 80 participants (planned) · Start Jul 6, 2023 · Primary completion Sep 30, 2025
Drug: 9MW1911; Placebo · For: Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Sites: Baotou, China; Beijing, China; Changsha, China · 22 sites in all
Mabwell (Shanghai) Bioscience Co., Ltd.Industry
NCT05803902 · 48 participants · Start Dec 15, 2021 · Primary completion Mar 6, 2023
Drug: Experimental drug 9MW1911; Placebo · For: Asthma; COPD; Atopic Dermatitis
Sites: Beijing, China
Mabwell (Shanghai) Bioscience Co., Ltd.Industry
NCT05170243 · 28 participants · Start Jan 21, 2022 · Primary completion Jul 3, 2022
Drug: 9MW1911 Injection; 9MW1911 Injection Placebo · For: Asthma; COPD; Atopic Dermatitis
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of 9MW1911, an anti-ST2 monoclonal antibody: results from a first-in-human phase 1 study.
Zhao Q, Li Q, Wang Y, et al. · Front Pharmacol 2025
Also in development for Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- RC1416Phase 22 trials
Nanjing RegeneCore Biotech Co., Ltd. · Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Moderate to Severe Asthma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.